(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.95%) $83.05
(-1.16%) $1.619
(-0.28%) $2 340.60
(-0.05%) $27.52
(0.50%) $926.70
(-0.15%) $0.933
(-0.15%) $11.01
(-0.24%) $0.798
(0.00%) $92.17
0.79% HKD 5.08
Live Chart Being Loaded With Signals
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong...
Stats | |
---|---|
Tagesvolumen | 1.07M |
Durchschnittsvolumen | 9.19M |
Marktkapitalisierung | 31.92B |
EPS | HKD0 ( 2024-03-27 ) |
Last Dividend | HKD0.160 ( 2023-06-05 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 7.70 |
ATR14 | HKD0.0160 (0.32%) |
Volumen Korrelation
China Resources Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
China Resources Korrelation - Währung/Rohstoff
China Resources Finanzdaten
Annual | 2023 |
Umsatz: | HKD270.40B |
Bruttogewinn: | HKD42.36B (15.67 %) |
EPS: | HKD0.680 |
FY | 2023 |
Umsatz: | HKD270.40B |
Bruttogewinn: | HKD42.36B (15.67 %) |
EPS: | HKD0.680 |
FY | 2022 |
Umsatz: | HKD254.11B |
Bruttogewinn: | HKD39.13B (15.40 %) |
EPS: | HKD0.660 |
FY | 2021 |
Umsatz: | HKD236.81B |
Bruttogewinn: | HKD35.38B (14.94 %) |
EPS: | HKD0.600 |
Financial Reports:
No articles found.
China Resources Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.160 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0900 | 2017-05-24 |
Last Dividend | HKD0.160 | 2023-06-05 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | HKD0.980 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.49 | -- |
Div. Sustainability Score | 8.46 | |
Div.Growth Potential Score | 4.24 | |
Div. Directional Score | 6.35 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2362.HK | No Dividend Player | 2023-06-01 | Annually | 0 | 0.00% | |
1349.HK | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
0393.HK | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
6677.HK | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
1899.HK | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
0927.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
0057.HK | Ex Dividend Knight | 2023-09-01 | Semi-Annually | 0 | 0.00% | |
2883.HK | Ex Dividend Knight | 2023-06-07 | Annually | 0 | 0.00% | |
1480.HK | Ex Dividend Knight | 2023-06-08 | Sporadic | 0 | 0.00% | |
0551.HK | Ex Dividend Junior | 2023-09-12 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0158 | 1.500 | 9.68 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0156 | 1.200 | 9.48 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0800 | 1.500 | -0.222 | -0.334 | [0.1 - 1] |
payoutRatioTTM | 0.245 | -1.000 | 7.55 | -7.55 | [0 - 1] |
currentRatioTTM | 1.330 | 0.800 | 8.35 | 6.68 | [1 - 3] |
quickRatioTTM | 0.799 | 0.800 | -0.00494 | -0.00395 | [0.8 - 2.5] |
cashRatioTTM | 0.236 | 1.500 | 9.80 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.313 | -1.500 | 4.79 | -7.19 | [0 - 0.6] |
interestCoverageTTM | 4.41 | 1.000 | 9.48 | 9.48 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.054 | 2.00 | 9.47 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.678 | -1.500 | 3.29 | -4.93 | [0 - 2.5] |
grossProfitMarginTTM | 0.157 | 1.000 | -0.722 | -0.722 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0431 | 1.000 | -1.139 | -1.139 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.127 | 1.000 | -0.407 | -0.407 | [0.2 - 2] |
assetTurnoverTTM | 0.992 | 0.800 | 6.72 | 5.38 | [0.5 - 2] |
Total Score | 8.46 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.22 | 1.000 | 9.27 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0800 | 2.50 | -0.143 | -0.334 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.054 | 2.00 | 9.65 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.17 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.245 | 1.500 | 7.55 | -7.55 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0399 | 1.000 | -1.502 | 0 | [0.1 - 0.5] |
Total Score | 4.24 |
China Resources
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.